Serum GPER-1 and Oxidant/Antioxidant Levels on Retinopathy in Diabetic Patients

Kahramanmaras Sutcu Imam University120 enrolled

Overview

Observational, comparative, cross-sectional study

This study was conducted on G protein-mediated estrogen receptor 1 (GPER-1), which is thought to be effective in preventing the development of diabetic retinopathy (DR). There are studies proving that GPER-1 prevents neuroprotective effects and vascular pathology in many tissues. In the study, serum GPER-1 and oxidative stress biomarker levels were compared in diabetic patients and healthy control groups. GPER-1 was found to be significantly increased in diabetic patients. In addition, a positive correlation was found with oxidant markers. This may lead to new treatment models in the future.

Study Type

OBSERVATIONAL

Enrollment

120

Conditions

Diabetes Mellitus Diabetic Retinopathy Hormones

Interventions

The effect of GPER-1 on the formation of diabetic retinopathyDIAGNOSTIC_TEST

Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models

Eligibility

Sex: ALLMin age: 35 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 40 individuals were required to have Proliferative Diabetic Retinopathy (PDR); * 40 were required to have Non-PDR; * 40 were required to be healthy, without any systemic disease. Exclusion Criteria: * Glaucoma, * Ocular trauma sequelae, * Pathological myopia, * Non-diabetic retinopathy, * A history of previous ocular surgery, * Endocrine disorders (e.g.,thyroidopathy, adrenal gland disorders, pituitary pathologies), * Opacities interfering with fundus examination (e.g., corneal opacity, lens opacity, vitreous cloudiness other than diabetic haemorrhage).

Locations (1)

Abdullah Beyoğlu

Kahramanmaraş, None Selected, Turkey (Türkiye)

Outcomes

Primary Outcomes

G receptor-mediated protein-1 (GPER-1)

Variation of GPER-1 during the development of diabetic retinopathy

Time frame: Baseline

Oxidative/antioxidative stress markers (malondialdehyde [MDA])

Variation of oxidative/antioxidative stress markers during the development of diabetic retinopathy

Time frame: Baseline

Oxidative/antioxidative stress markers (catalase [CAT])

Variation of oxidative/antioxidative stress markers during the development of diabetic retinopathy

Time frame: Baseline

Oxidative/antioxidative stress markers (superoxide dismutase [SOD]

Variation of oxidative/antioxidative stress markers during the development of diabetic retinopathy

Time frame: Baseline

Thyroid stimulating hormone (TSH)

Variation of TSH during the development of diabetic retinopathy

Time frame: Baseline

Progesterone

Variation of progeterone during the development of diabetic retinopathy

Time frame: Baseline

oestradiol

Variation of oestradiol during the development of diabetic retinopathy

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.